Pancreatic Cancer Highlights From ASCO GI 2026

Fiyinfolu Balogun, MD, PhD Memorial Sloan Kettering Cancer Center | Angelo Pirozzi, MD Mayo Clinic Arizona

January 23, 2026

Copy Link Share
Key Points

  • Elraglusib, a novel GSK-3ß inhibitor, plus chemotherapy improved overall survival (OS) versus chemotherapy alone in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

  • The OS benefit was consistent across liver metastases, performance score, and baseline CA 19-9 subgroups.

  • The current data may not be robust enough to change practice, but they provide support for continuing to pursue combination regimens in pancreatic cancers.

Elraglusib in mPDAC Data From 2026 ASCO GI 

During the Advancements in Oncology live event, Angelo Pirozzi, MD, of Mayo Clinic Arizona, spoke with Fiyinfolu Balogun, MD, PhD, of Memorial Sloan Kettering Cancer Center, to discuss recent data on targeted therapies for patients with pancreatic cancer presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI). The doctors highlighted phase 2 randomized trial data on elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in untreated mPDAC.

In the study, median OS was 10.1 months with elraglusib compared with 7.2 months with GnP (HR, 0.62; P = .01), according to the presentation. Between the elraglusib arm and the GnP arm, 1-year OS was 44.1% versus 22.3%, 18-month OS was 20.5% versus 4.4%, and 24-month OS was 13.2% versus 0%, respectively. The objective response rate was 28.4% with elraglusib and 21.8% with GnP. Median PFS was comparable between the arms (5.6 months vs 5.1 months; HR, 0.9; P = not significant).

These data are not necessarily practice-changing, but they provide more support for combining targeted therapies and chemotherapy, which may improve disease control for patients who might otherwise progress on chemotherapy alone, said Dr. Balogun. Future trials may explore additional combinations of immunotherapies, radioligands, and chemotherapies, he added.